Recent trading context for Phibro Animal Health

Phibro Animal Health (PAHC) has drawn fresh attention after a sharp pullback in its share price, with the stock down about 39% over the past month and 37% over the past 3 months.

Despite the recent pullback, the stock’s 1 year total shareholder return of 39.53% and 3 year total shareholder return of 173.78% point to strong longer term momentum compared with the weaker 30 day and 90 day share price returns.

If this kind of sharp swing has you thinking about where else capital could work, it might be a good time to widen your search using our screener of 20 top founder-led companies

With shares now well below analysts’ price target and the stock still carrying a stronger multi year total return record, the key question is whether this pullback signals undervaluation or whether the market is already pricing in future growth.

Most Popular Narrative: 31% Undervalued

The most followed narrative currently places Phibro Animal Health's fair value at $48.50 compared with the last close of $33.68. This frames a sizable valuation gap that hinges on how earnings quality and growth durability are assessed.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non-repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits, implying the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

Want to see what keeps this story attractive despite those limits on one off gains? The narrative leans on steadier growth, firmer margins, and a different earnings multiple.

Result: Fair Value of $48.50 (UNDERVALUED)

However, there are still clear risks, including tighter regulation of antibiotic use and slower vaccine and nutritional specialties momentum, that could challenge this undervaluation case.

Next Steps

With sentiment clearly mixed, and with both risks and rewards on the table, it makes sense to review the data now and decide where you stand using the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss out on other setups that fit your style, so use the screener and keep your watchlist strong.

• Target reliable cash generators by scanning for companies in the solid balance sheet and fundamentals stocks screener (46 results) that can better support their operations and future plans.
• Hunt for potential bargains using the 46 high quality undervalued stocks to spot stocks where fundamentals and price may not fully line up.
• Strengthen your income focus by checking out the 10 dividend fortresses and see which companies offer higher yields with a focus on consistency.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.